Trade

with

Valeant Pharmaceuticals International Inc
(NYSE: VRX)
AdChoices
124.78
+4.57
+3.80%
After Hours :
123.76
-1.02
-0.82%

Open

121.13

Previous Close

120.21

Volume (Avg)

3.40M (2.83M)

Day's Range

120.12-127.43

52Wk Range

102.60-153.10

Market Cap.

40.10B

Dividend Rate ( Yield )

-

Beta

0.90

Shares Outstanding

333.57M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Drug Manufacturers – Specific & Generic
Highlights
Analyst Recommendation: Buy
    • Revenue

    • -

    • Net Income

    • -

    • Market Cap.

    • 40.10B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -9.91

    • PEG (Price/Earnings Growth) Ratio

    • 0.65

    • Beta

    • 0.90

    • Forward P/E

    • 11.51

    • Price/Sales

    • 5.60

    • Price/Book Value

    • 7.92

    • Price/Cash flow

    • 28.82

      • EBITDA

      • -

      • Return on Capital %

      • -3.13

      • Return on Equity %

      • -13.62

      • Return on Assets %

      • -3.13

      • Book Value/Share

      • 15.76

      • Shares Outstanding

      • 333.57M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • 0.10 (8/30/2010)

      • Dividend Declaration Date

      • 8/6/2010

      Analyst Recommendation
      10/17/2014
      Buy
        • 1 Year Price Target

        • 178.69

        • Credit Rating

        • UR+

        • Analysts

        • 12

        • EPS Estimate

        • -

        • Cashflow Estimate

        • 13.41

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 86.30

          • 7.67

          • Net Income

            YTD/YTD (last year)

          • -

          • -26.33

          • Net Income

            Q/Q (last year)

          • 1,064.80

          • 197.54

          • Sales (Revenue)

            5-Year Annual Average

          • 50.10

          • -5.42

          • Net Income

            5-Year Annual Average

          • -

          • 3.16

          • Dividends

            5-Year Annual Average

          • -

          • -0.13

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 67.99

            • 64.72

            • Pre-Tax Margin

            • -14.52

            • 13.77

            • Net Profit Margin

            • -9.91

            • 10.84

            • Average Gross Margin

              5-Year Annual Average

            • 69.80

            • 67.80

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -6.70

            • 15.58

            • Average Net Profit Margin

              5-Year Annual Average

            • -1.60

            • 343.47B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 3.24

              • 0.33

              • Current Ratio

              • 2.07

              • 1.52

              • Quick Ratio

              • 0.92

              • 0.87

              • Interest Coverage

              • -0.09

              • 6.77

              • Leverage Ratio

              • 5.31

              • 1.91

              • Book Value/Share

              • 15.76

              • 16.21

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -51.28

                • 63.29

                • P/E Ratio 5-Year High

                • -68.67

                • 237.47

                • P/E Ratio 5-Year Low

                • -5.79

                • 19.71

                • Price/Sales Ratio

                • 5.13

                • 3.53

                • Price/Book Value

                • 7.25

                • 3.31

                • Price/Cash Flow Ratio

                • 28.82

                • 21.23

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -13.62

                    (-2.40)

                  • 7.86

                    (9.58)

                  • Return on Assets %

                    (5-Year Average)

                  • -3.13

                    (0.60)

                  • 4.14

                    (5.54)

                  • Return on Capital %

                    (5-Year Average)

                  • -0.33

                    (-1.70)

                  • 5.59

                    (7.66)

                  • Income/Employee

                  • -

                  • 27.79k

                  • Inventory Turnover

                  • 3.35

                  • 1.80

                  • Asset Turnover

                  • 0.32

                  • 0.38

                  Current Historical
                  Ownership

                  Institutional Ownership

                  95.95%

                  Top 10 Institutions

                  39.17%

                  Mutual Fund Ownership

                  32.73%

                  Float

                  82.08%

                  5% / Insider Ownership

                  2.09%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Sequoia Fund

                  •  

                    11,309,482

                  • -0.09

                  • 3.37

                  • T. Rowe Price Growth Stock Fund

                  •  

                    3,968,200

                  • 25.22

                  • 1.18

                  • iShares S&P/TSX 60

                  •  

                    3,047,724

                  • 9.62

                  • 0.91

                  • OMGB Orbis Global Equity USD

                  •  

                    2,470,703

                  • 25.28

                  • 0.74

                  • JPMorgan Large Cap Growth

                  •  

                    2,465,200

                  • 0.00

                  • 0.73

                  • T. Rowe Price Health Sciences Fund

                  •  

                    2,332,400

                  • 11.73

                  • 0.70

                  • Vanguard Total Intl Stock Idx Fund

                  •  

                    1,911,280

                  • 1.94

                  • 0.57

                  • Davis New York Venture Fund

                  •  

                    1,763,700

                  • 0.00

                  • 0.53

                  • Fidelity Canadian Balanced Class

                  •  

                    1,672,528

                  • 0.00

                  • 0.53

                  • Principal MidCap Fund

                  •  

                    1,562,799

                  • 0.77

                  • 0.47

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Ruane, Cunniff & Goldfarb Inc

                  •  

                    34,298,384

                  • +0.24%

                  • 10.23

                  • Valueact Capital Management, L.p.

                  •  

                    18,928,899

                  • 0.00%

                  • 5.64

                  • T. Rowe Price Associates, Inc.

                  •  

                    16,455,707

                  • +17.07%

                  • 4.91

                  • Fidelity Management and Research Company

                  •  

                    12,999,967

                  • -35.59%

                  • 3.89

                  • Viking Global Investors LP

                  •  

                    11,830,932

                  • +27.27%

                  • 3.53

                  • Lone Pine Capital LLC

                  •  

                    10,089,450

                  • +14.44%

                  • 3.01

                  • BMO Asset Management Inc.

                  •  

                    7,779,802

                  • -2.42%

                  • 2.32

                  • Toronto-Dominion Bank

                  •  

                    7,041,461

                  • -9.36%

                  • 2.11

                  • Brave Warrior Advisors LLC

                  •  

                    6,050,442

                  • +8.19%

                  • 1.80

                  • MFS Investment Management K.K.

                  •  

                    5,797,126

                  • -1.07%

                  • 1.73

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Drug Manufacturers – Specific & Generic

                  Type

                  High Yield

                  Style

                  Large Growth

                  Valeant Pharmaceuticals International Inc was formed on 29th March, 1994 and was formerly known as Biovail Corporation. It is a multinational, specialty pharmaceutical and medical device company that develops, manufactures, and marke...morets a range of branded, generic and branded generic pharmaceuticals, over-the-counter products "OTC", and medical devices such as contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices, which are marketed directly or indirectly in over 100 countries. The Company operates in two segments; Developed Markets and Emerging Markets. In the Developed Markets segment, it focuses its efforts in the eye health, dermatology, and neurology therapeutic classes. The Developed Markets segment consists of four reporting units based on geography, namely;...more U.S., Canada and Australia, Western Europe, and Japan. In the Emerging Markets segment, it focuses on branded generics, OTC products, and medical devices. The Emerging Markets segment consists of three reporting units based on geography, namely; Central & Eastern Europe, Middle East and North Africa, Latin America, and Asia & South Africa. Its principal pharmaceutical products are; Wellbutrin XL®, Xenazine®, Zovirax® Cream, Zovirax®, Lotemax®, Arestin® and Prolensa®. Its principal OTC products are; PreserVision®, ReNu Multiplus®, Ocuvite®, Artelac™, and CeraVe®. The Company relies on a combination of contractual provisions, confidentiality policies and procedures and patent, trademark, copyright and trade secrecy laws to protect the proprietary aspects of its technology and business. Its top four geographic markets are; the U.S. and Puerto Rico, Canada, Poland and Russia. The Company competes with specialty and other pharmaceutical companies, medical device companies, biotechnology companies, OTC companies and generic manufacturers, in the U.S., Canada, the EU and in other countries in which it market its products. The principal raw materials, including active pharmaceutical ingredient, used by the Company "or its third party manufacturers" for its various products are purchased in the open market or are otherwise available from several sources. The Company is subject to extensive U.S. federal and state health care marketing and fraud and abuse regulations, such as the federal False Claims Act, federal and provincial marketing regulation in Canada and similar regulations in foreign countries in which it may conduct its business.lessless

                  Key People

                  J. Michael Pearson

                  CEO/Chairman of the Board/Director

                  Mr. Howard Schiller

                  CFO/Chief Accounting Officer/Director/Executive VP

                  Laizer D. Kornwasser

                  Executive VP/Other Corporate Officer

                  Mr. Robert Roswell Chai-Onn

                  Executive VP/General Counsel/Other Corporate Officer/Other Executive Officer

                  Mr. Brian M. Stolz

                  Executive VP, Divisional/Other Executive Officer

                  • Valeant Pharmaceuticals International Inc

                  • 2150 Street Elzéar Boulevard West

                  • Laval, QC H7L 4A8B

                  • CAN.Map

                  • Phone: +1 514 744-6792

                  • Fax: +1 514 744-6272

                  • valeant.com

                  Incorporated

                  1994

                  Employees

                  17,200

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: